MMX® mesalazine for the treatment of patients with ulcerative colitis: the impact of treatment on health related quality of life

被引：0
|
作者：
Kane, S. [1 ]
Yen, L. [2 ]
Yarlas, A. [3 ]
Karlstadt, R. [2 ]
Solomon, D. [2 ]
Hodgkins, P. [2 ]
机构：
[1] Mayo Clin, Dept Med, Rochester, MN USA
[2] Shire Pharmaceut Inc, Wayne, PA USA
[3] QualityMetric Inc, Lincoln, RI USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2010年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A92 / A92
页数：1
相关论文
共 50 条
  • [21] COMBINED MESALAZINE MMX PLUS RECTAL MESALAZINE IN THE TREATMENT OF MILD TO MODERATELY ACTIVE ULCERATIVE PROCTITIS
    Cuomo, A.
    D'Auria, M. V.
    Miranda, A.
    Sgambato, D.
    Cardone, C.
    Vicinanza, G.
    Di Fenza, S.
    Gallo, V.
    Romano, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2015, 47 : E139 - E139
  • [22] A safety evaluation of budesonide MMX for the treatment of ulcerative colitis
    Bezzio, Cristina
    Festa, Stefano
    Zerboni, Giulia
    Papi, Claudio
    Manes, Gianpiero
    Saibeni, Simone
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (04) : 437 - 444
  • [23] MMX mesalazine is well tolerated during 12 months' maintenance treatment of mild-to-moderate ulcerative colitis
    Kamm, M. A.
    Lichtenstein, G. R.
    Sandborn, W. J.
    Barrett, K.
    Joseph, R. E.
    [J]. GUT, 2007, 56 : A113 - A113
  • [24] The Impact of Biological Interventions for Ulcerative Colitis on Health-Related Quality of Life
    Whitehead, Lisa
    [J]. AMERICAN JOURNAL OF NURSING, 2016, 116 (11) : 21 - 23
  • [25] The impact of biological interventions for ulcerative colitis on health-related quality of life
    LeBlanc, Katie
    Mosli, Mahmoud H.
    Parker, Claire E.
    MacDonald, John K.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
  • [26] IMPACT OF ACTIVE ULCERATIVE COLITIS ON HEALTH RELATED QUALITY OF LIFE AND PRODUCTIVITY LOSS
    Van Assche, G.
    Peyrin-Biroulet, L.
    Fan, T.
    Lara, N.
    Lynam, M.
    Rojas-Farreras, S.
    Ding, Q.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A40 - A40
  • [27] ECONOMIC IMPLICATIONS OF BUDESONIDE MMX® ADVANTAGE IN ULCERATIVE COLITIS TREATMENT OVER SYSTEMIC STEROIDS: BUDESONIDE MMX® DECREASES ULCERATIVE COLITIS TREATMENT COSTS
    Bierut, A.
    Jesionowski, M.
    Pruszko, C.
    Jachimowicz, M.
    Kowalczyk, M.
    Ksiazek, P.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A314 - A315
  • [28] The budgetary impact of 2 g mesalazine for the treatment of mild to moderate ulcerative colitis
    Lovelace, I.
    Tate, E.
    Knapp, S.
    Masure, J.
    Shields, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S200 - S201
  • [29] Maintenance of clinical remission with MMX® mesalazine 2.4 g/day in patients with mild-to-moderate ulcerative colitis, irrespective of prior treatment
    Kane, S.
    Solomon, D.
    Palmen, M.
    Barrett, K.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A91 - A91
  • [30] The Impact of Endoscopic Inflammation and Mucosal Healing on Health-related Quality of Life in Ulcerative Colitis Patients
    Theede, Klaus
    Kiszka-Kanowitz, Marianne
    Nordgaard-Lassen, Inge
    Nielsen, Anette Mertz
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 (08): : 625 - 632
12345